GlassScriptPhysician profile
Janet I Bruce
NPI 1639148323
$1,028.89
in general payments reported to CMS, 2019-2025
26 companies · $187 in 2025
The $187 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $48.43 · 2023: $140 · 2024: $653 · 2025: $187.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $950 · Education: $30.65.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $949.81 |
| Education | $30.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Beigene USA, INC. | $148.94 | 2023-2024 | Brukinsa, Tevimbra |
| Merck Sharp & Dohme LLC | $97.61 | 2024 | Keytruda, Welireg, Lynparza |
| Astrazeneca Pharmaceuticals LP | $87.52 | 2024-2025 | Enhertu |
| Daiichi Sankyo INC. | $68.35 | 2021-2025 | Enhertu, Vanflyta |
| Abbvie INC. | $54.57 | 2024-2025 | |
| Pfizer INC. | $46.96 | 2024-2025 | |
| Array Biopharma INC | $40.99 | 2024 | Braftovi, Mektovi, Tukysa |
| Incyte Corporation | $38.05 | 2024 | Jakafi |
| Glaxosmithkline, LLC. | $36.42 | 2024-2025 | Zejula, Jemperli, Ojjaara |
| Sobi, INC | $35.06 | 2024 | |
| Novartis Pharmaceuticals Corporation | $31.57 | 2025 | |
| Janssen Biotech, INC. | $31.28 | 2021 | |
| Genzyme Corporation | $30.60 | 2024 | |
| Ipsen Biopharmaceuticals, INC | $29.71 | 2024 | Onivyde |
| Tersera Therapeutics LLC | $29.36 | 2024 | Zoladex |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $26.83 | 2024 | Fruzaqla |
| Blueprint Medicines Corporation | $23.32 | 2024 | Ayvakit |
| Gilead Sciences, INC. | $22.71 | 2024 | |
| Adc Therapeutics America, INC. | $22.16 | 2024 | |
| Sumitomo Pharma America, INC. | $21.93 | 2024 | Orgovyx |
| Celgene Corporation | $20.49 | 2024 | Reblozyl |
| Bayer Healthcare Pharmaceuticals INC. | $19.14 | 2024 | |
| Pharmaessentia USA Corporation | $17.48 | 2025 | Besremi |
| Rigel Pharmaceuticals, INC. | $16.59 | 2024 | Tavalisse, Rezlidhia |
| Agios Pharmaceuticals, INC. | $16.39 | 2024 | Pyrukynd |
| Emd Serono, INC. | $14.86 | 2023 | Bavencio |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Janet Bruce listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.